Filing Flows

Filing Flows › Ionis Pharmaceuticals (IONS) › Who owns the stock

Who owns Ionis Pharmaceuticals (IONS) stock

464 funds reported Ionis Pharmaceuticals (IONS) shares in their latest 13F filings, worth $14.9B in all. The largest holder is FMR LLC ($2.0B). Last quarter 238 funds added to their stakes and 190 cut them.

Largest holders of IONS (13F)Largest holders of IONS (13F)FMR LLC$2.0BCapital World Investors$1.7BVanguard Group$1.3BBlackRock$849MVanguard Portfolio Management LLC$623MWellington Management Group LLP$607MVanguard Capital Management LLC$572MTwo Sigma Investments, LP$496MRoyal Bank of Canada$490MState Street$344M

Largest holders (13F)

FundSharesValueChangeQuarter
FMR LLC24,631,956$2.0Bincrease2026-06-30
Capital World Investors21,669,226$1.7Bincrease2026-06-30
Vanguard Group16,440,459$1.3Bdecrease2025-12-31
BlackRock10,704,660$849Mincrease2026-06-30
Vanguard Portfolio Management LLC7,859,529$623Mincrease2026-06-30
Wellington Management Group LLP7,651,415$607Mincrease2026-06-30
Vanguard Capital Management LLC7,211,497$572Mincrease2026-06-30
Two Sigma Investments, LP6,252,342$496Mincrease2026-06-30
Royal Bank of Canada6,182,479$490Mincrease2026-06-30
State Street4,334,848$344Mincrease2026-06-30
T. Rowe Price Investment Management3,959,372$314Mdecrease2026-06-30
Geode Capital Management, LLC3,584,024$295Mdecrease2026-06-30
Price T Rowe Associates3,184,500$252Mincrease2026-06-30
Artisan Partners Limited Partnership2,640,024$209Mincrease2026-06-30
Tweedy, Browne Co LLC2,280,311$181Mincrease2026-06-30

Ionis Pharmaceuticals' latest quarter

Ionis Pharmaceuticals, Q2 2026: revenue $268M (-41% year over year), operating margin -38.2%, net loss $115M, operating cash flow $566M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most IONS stock?

By the latest 13F filings: FMR LLC ($2.0B); Capital World Investors ($1.7B); Vanguard Group ($1.3B); BlackRock ($849M); Vanguard Portfolio Management LLC ($623M).

What is the short interest in IONS?

20,653,026 shares were sold short at the 2026-10-15 settlement, -8.24% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.